company background image
NAVB

Navidea Biopharmaceuticals NYSEAM:NAVB Stock Report

Last Price

US$0.25

Market Cap

US$8.1m

7D

4.9%

1Y

-77.8%

Updated

06 Dec, 2022

Data

Company Financials
NAVB fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health0/6
Dividends0/6

NAVB Stock Overview

Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics.

Navidea Biopharmaceuticals, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Navidea Biopharmaceuticals
Historical stock prices
Current Share PriceUS$0.25
52 Week HighUS$1.34
52 Week LowUS$0.20
Beta1.36
1 Month Change7.74%
3 Month Change-25.14%
1 Year Change-77.83%
3 Year Change-75.20%
5 Year Change-97.03%
Change since IPO-99.81%

Recent News & Updates

Recent updates

Need To Know: Navidea Biopharmaceuticals, Inc. (NYSEMKT:NAVB) Insiders Have Been Buying Shares

Feb 10
Need To Know: Navidea Biopharmaceuticals, Inc. (NYSEMKT:NAVB) Insiders Have Been Buying Shares

Shareholder Returns

NAVBUS BiotechsUS Market
7D4.9%3.2%1.1%
1Y-77.8%-6.5%-17.6%

Return vs Industry: NAVB underperformed the US Biotechs industry which returned -6.5% over the past year.

Return vs Market: NAVB underperformed the US Market which returned -17.6% over the past year.

Price Volatility

Is NAVB's price volatile compared to industry and market?
NAVB volatility
NAVB Average Weekly Movement10.9%
Biotechs Industry Average Movement11.2%
Market Average Movement7.4%
10% most volatile stocks in US Market15.6%
10% least volatile stocks in US Market3.3%

Stable Share Price: NAVB is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 11% a week.

Volatility Over Time: NAVB's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
198313n/ahttps://www.navidea.com

Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates through two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages for a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (PET), gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases.

Navidea Biopharmaceuticals, Inc. Fundamentals Summary

How do Navidea Biopharmaceuticals's earnings and revenue compare to its market cap?
NAVB fundamental statistics
Market CapUS$8.08m
Earnings (TTM)-US$17.38m
Revenue (TTM)US$115.39k

70.2x

P/S Ratio

-0.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
NAVB income statement (TTM)
RevenueUS$115.39k
Cost of RevenueUS$134.91k
Gross Profit-US$19.52k
Other ExpensesUS$17.37m
Earnings-US$17.38m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.54
Gross Margin-16.92%
Net Profit Margin-15,065.93%
Debt/Equity Ratio-38.4%

How did NAVB perform over the long term?

See historical performance and comparison